==== Front Rev Bras Ginecol Obstet Rev Bras Ginecol Obstet 10.1055/s-00030576 RBGO Gynecology & Obstetrics 0100-7203 1806-9339 Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil 30352460 10.1055/s-0038-1673366 180148 Original Article Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk Associação entre o polimorfismo do gene metalopeptidase de matriz 9 e o risco de câncer de mamaFelizi Rogério Tadeu 1 Veiga Melissa Gonzalez 1 Carelli Filho Ivo 1 Souto Ricardo Peres do 2 Fernandes César Eduardo 1 Oliveira Emerson 1 1 Department of Gynecology, Faculty of Medicine of ABC, Santo André, SP, Brazil 2 Department of Biochemistry, Faculty of Medicine of ABC, Santo André, SP, Brazil Address for correspondence Rogério Tadeu Felizi, MD Av. Lauro Gomes, 2000, 09060-870Vila Sacadura Cabral, Santo André, SPBrazilrogerio.felizi@gmail.com 10 2018 1 10 2018 40 10 620624 02 5 2018 19 7 2018 https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective Epidemiological studies have shown evidence of the effect of genetic variations in the pathogenesis of breast cancer and have suggested a relationship of the disease with genetic polymorphisms. Matrix metallopeptidase 9 (MMP-9) is a collagenase responsible for the degradation of type IV collagen, the major component of the basement membrane, and other essential extra cellular matrix components, being involved in the tumor cell invasion and metastasis. Our objective was to evaluate the relationship between the MMP-9-1562 C/T polymorphism (rs 3918242) and the risk of developing breast cancer. Methods In this case-control study, the frequency of the MMP-9-1562 C/T polymorphism (rs 3918242) was determined in 148 women with breast cancer and 245 women without the disease. The DNA was extracted from plasma samples, and the gene was amplified by polymerase chain reaction (PCR); the presence of the polymorphism was determined using restriction enzymes. Results After adjusting for confounding variables, we found that the polymorphism was not associated with the occurrence of breast cancer (odds ratio [OR] = 1.159, 95% confidence interval [CI]: 0.6625–1.997, p = 0.5964). We also found no association with more advanced disease, the presence of hormone receptors, human epidermal growth factor receptor 2 (HER2) overexpression, or rate of tumor cell proliferation. Conclusion We did not observe a relationship between MMP-9–1562 C/T polymorphism (rs 3918242) and the occurrence of breast cancer. Resumo Objetivo Estudos epidemiológicos vêm demonstrando evidências da influência de variações genéticas na patogênese do câncer de mama, e têm sugerido associação de polimorfismos com uma maior susceptibilidade à doença. A metalopeptidase de matriz 9 (MMP-9) é uma colagenase responsável pela degradação do colágeno tipo IV, o maior componente da membrana basal, e outros componentes essenciais da matriz extra celular, estando envolvido na invasão da célula tumoral e metástase. Nosso objetivo foi avaliar a associação entre o polimorfismo da 1562 C/T (rs 3918242) do gene MMP-9 e o desenvolvimento da neoplasia mamária. Métodos Neste estudo caso–controle, a frequência de polimorfismo 1562 C/T (rs 3918242) do MMP-9 foi determinada em 148 mulheres com câncer de mama e 245 mulheres sem a doença. O DNA foi extraído do plasma e o gene foi amplificado por meio de reação em cadeia da polimerase (RCP). O polimorfismo foi determinado por enzimas de restrição. Resultados O polimorfismo, após o ajuste para variáveis confundidoras, não foi associado com a ocorrência de câncer de mama (razão de possibilidade [RP] = 1,159, intervalo de confiança de 95% [IC95]: 0,6625–1,997, p = 0,5964). Também não foi demonstrado associação com estadiamentos mais avançados, presença de receptores hormonais, superexpressão de HER2 e tampouco com a taxa de proliferação celular do tumor. Conclusão Não observamos relação entre o polimorfismo 1562 C/T (rs 3918242) do gene MMP-9 e a ocorrência de câncer de mama. Keywords MMP-9 metalloproteinase breast cancer genetic polymorphism genetics single-nucleotide polymorphisms Palavras-chave metaloproteinase MMP-9 câncer de mama polimorfismo genético genética polimorfismos de nucleotídeo único ==== Body pmcIntroduction Breast cancer is the most common type of cancer in the female population when disregarding cases of non-melanoma skin cancer. The mortality rate due to the disease presents an upward curve,1 contributing to make breast cancer a major public health problem and an important cause of mortality in adults.2 In 2018, 59,700 new cases were estimated in Brazil, representing an incidence rate of more than 56 cases per 100,000 women.1 Approximately 10 to 15% of breast cancer patients have a previous family history of the disease; however, only 5% can be explained by mutation of genes such as BRCA1 and BRCA2.3 Regarding family risk for the development of the disease, it is necessary to consider the influence of environmental factors and genetic variations that may alter the predisposition to the risk of breast cancer.4 Metalloproteinases (MMPs) are a family of endopeptidases participating in the degradation of extra cellular matrix and basement membrane barriers.5 6 7 Some members of the MMPs family have been shown to promote tumor growth, angiogenesis, invasion and metastasis in cancer patients.8 9 10 Matrix metallopeptidase 9 (MMP-9) is a collagenase responsible for the degradation of type IV collagen, the major component of the basement membrane, and others essential extra cellular matrix component̀s, being involved in the tumor cell invasion and metastasis.11 12 The gene MMP-9 is located on chromosome region 20q11.2-q13.1.13 Genetic variation may alter MMP-9 expression, influencing breast cancer susceptibility.14 Differential expression of MMP-9 reflects the degree of differentiation of breast cancer cells and that its overexpression is closely related with the most aggressive subtypes.15 Several single-nucleotide polymorphisms (SNPs) have been reported to be correlated with tumor progression and worse disease prognosis. Among MMP-9 polymorphisms, 1562 C/T (rs 3918242), a C to T substitution at −1562 bp, is the most studied.14 Researches have been performed to confirm the relationship between the pointed polymorphism and breast cancer susceptibility, however results are inconclusive.14 In this clinical, cross-sectional case-control study, we evaluated the potential relationship of the MMP-9 gene polymorphism with breast cancer and aggressiveness of the disease. Methods We studied 393 women, recruited between 2013 and 2015, who were followed up in the mastology sector of the division of gynecology of the Faculdade de Medicina do ABC (FMABC). The participants were divided into two groups: 148 with histologically confirmed diagnosis of breast cancer (case group) and 245 without the disease, with normal clinical and mammographic examinations (control group). For the patients with breast cancer, staging of the disease was retrieved from the patients' records, based on the tumor, node and metastasis (TNM) classification of malignant tumors. Immunohistochemical analysis of the tumor was performed to determine the presence of estrogen receptors (detected using the EP1 clone), human epidermal growth factor receptor 2 (HER2) overexpression and Ki67. Tumors exhibiting at least 1% of tumor cells staining for estrogen receptor were considered positive. Breast cancers were tested for HER2 overexpression by immunohistochemistry (IHC), and cases showing equivocal (2 + ) staining by IHC required reflex testing by HHER2 D-FISH. The Ki67 cut-off was considered 25%. Clinical data were collected with the use of a questionnaire; the following data were recorded: age, age at menarche and last menstruation, number of pregnancies, previous use of hormonal medications, breastfeeding, history of smoking, alcohol consumption and endocrine diseases. The patients included were informed about the study and signed a consent form. Venous blood samples were collected from women of both groups, and genomic DNA was extracted using the Illustra blood genomic prep mini spin reagent kit (GE Healthcare, Chicago, IL, USA), following the manufacturer's instructions. The presence of the MMP-9 polymorphism was determined following the PCR-RFLP procedure described by Zhang et al (1999).16 For the amplification of the promoter region of the gene by polymerase chain reaction (PCR), the following primers were used: 5′-GCC TGG CAC ATA GTA GGC CC-3′ e 5′- CTT CCT AGC CAG CCG GCA TC -3′. The 435-bp PCR products were treated with the Sphl restriction enzyme, and the restriction fragments were separated by electrophoresis in 2.5% agarose stained with ethidium bromide. At the end of the analysis, C/C homozygotes should present a single 435-bp band, T/T homozygotes should present two bands of 247 and 188 bp, and T/C heterozygotes should present three bands of 435, 247 and 188 bp. To assess the association between the study groups and the categorical variables, we used the frequency chi-squared test, whereas the continuous variables were analyzed using the unpaired t-test. The Hardy-Weinberg equilibrium was also tested using the chi-squared test. After the stratification of the groups, the effect of the MMP-9 polymorphism on breast cancer development was estimated by the odds ratio (OR), obtained by the binary logistic regression model, using the SPSS software, version 23.0 (IBM Corp., Armonk, NY, USA). The confidence interval adopted was 95% (95%CI), and the value for rejection of the null hypothesis was set at 0.05 or 5% (α ≤ 0.05). The project was approved by the Research Ethics Committee of the institution under number 169/2010. Results A total of 148 women were included in the case group, and 245 women were included in the control group. The clinical and epidemiological characteristics of both groups are described in Table 1. Both groups presented homogeneity for almost all of the characteristics evaluated, with similar proportions of women over 50 years of age, menopausal women and/or women who used hormone therapy in the case and control groups. The variable parity and the age at first pregnancy also showed no significant differences between the groups. Cases were more likely to use oral contraceptives than controls, with frequency of use at 22.3% and 6.1%, respectively (p < 0.0001). The family history of breast cancer (p = 0.04) was more frequent in women who presented with the disease, with a difference of almost 10% between the groups. Table 1 Matrix metallopeptidase 9 polymorphism—clinical characteristics of cases and controls Characteristics Cases (n = 148) Controls (n = 245) p-value Age (years)# 57.8 ± 0.9 59.5 ± 0.6 0.134 Age at menarche (years)# 12.9 ± 0.1 13.2 ± 0.1 0.059 Postmenopause* 121 (81.7%) 82. 7% 0.785 Parity* 2.6 ± 0.12 2.9 ± 0.09 0.067 Breastfeeding* 116 (78.4%) 207 (84.5%) 0.13 Age at first pregnancy# 23.1 ± 0.45 22.7 ± 0.3 0.54 Use of oral contraceptive* 33 (22.3%) 15 (6.1%) < 0.0001** Use of hormone therapy* 13 (8.7%) 36 (14.7%) 0.114 Family history of breast cancer* 25 (16.9%) 18 (7.3%) 0.004** Continuous variables: values expressed as the mean and standard deviation; Categorical variables: values expressed as numbers and percentages; # Unpaired t-test; * Chi-squared test; ** Significant values Genotyping and frequency of the alleles are described in Table 2. The distribution of the genotypes is in genetic equilibrium according to the Hardy-Weinberg principle in the case and control groups. Table 2 Matrix metallopeptidase 9 polymorphism and the occurrence of breast cancer CC TC + TT OR crude (CI) OR adjusted (CI)* Cases 115 (82.7%) 24 (17.3%) 1.159 (0.6625–1.997) p = 0.5964 Controls 186 (80.5%) 45 (19.5%) Abbreviations: CI, confidence interval; OR, odds ratio. Due to the low incidence of the TT genotype in the studied population, we chose to analyze the results comparing the wild homozygous group (CC) with the polymorphic group (TC + TT). After adjusting for oral contraceptive use and family history of breast cancer, the presence of the T allele and the TT (TC + TT) genotype of the MMP-9 polymorphism was not directly associated with tumor occurrence (OR = 1.159, 95%CI: 0.6625–1.997, p = 0.5964). In addition, no statistically significant difference was found between the polymorphisms when analyzing according to the staging of the disease, estrogen receptor status, HER2 overexpression or non-overexpression, or cell proliferation rate represented by Ki67, as shown in Table 3. Table 3 Evaluation of matrix metallopeptidase 9 polymorphism and staging, status of estrogen receptor, HER2 and Ki67 CC TC + TT p-value* Staging IA–IIB Staging IIB–IV 90 (81%) 25 (89%) 21 (19%) 3 (11%) 0.4075 Estrogen receptor+ 86 (81.9%) 19 (18.1%) 0.796 Estrogen receptor - 29 (85.3%) 5 (14.7%) HER2 + 21 (87.5%) 3 (12.5%) 0.766 HER2 - 94 (81.7%) 21 (18.3%) Ki67 ≤ 25% 58 (85.3%) 10 (14.7%) 0.244 Ki67 > 25% 41 (75.9%) 13 (24.1%) Abbreviation: HER2, human epidermal growth factor receptor 2. * Chi-squared test Discussion Hereditary predisposition to breast cancer significantly influences the screening and follow-up of women at high risk for developing the disease, enabling early diagnosis, personalized conduct and family counseling. However, in patients with a personal or family history of breast cancer, a specific genetic predisposition is identified in less than 30% of cases.17 Thus, it seems that the effect of low-penetrance gene polymorphisms on the risk for breast cancer is relevant only in polygenic forms.17 Studies have demonstrated that degradation of extra cellular matrix and basement membrane by MMPs play an important role in tumorigenesis by modulating cell proliferation, apoptosis, tumor invasion and metastasis.18 The role played by MMP-9 in the malignancy and the growth of the tumor is an important one.14 Numerous single-nucleotide polymorphisms (SNPs) have already been identified in the MMP-9 gene, and the most common variant is 1562 C/T (rs 3918242). Our study demonstrated that the T allele and the TT genotype of the MMP-9 polymorphism were not directly associated with the occurrence of breast cancer, as shown in Table 2. The association between this polymorphism and the disease has already been studied by groups from several countries, without a direct relationship being established. An Indian study revealed that the frequency of T-allele of MMP-9–1562 C/T promoter polymorphism was found to be predominant in breast cancer group compared with controls, with a 1.44 folds increased risk for breast cancer.19 Merdad et al20 showed that MMP-9 is a reliable potential candidate diagnostic biomarker and drug target in breast cancer. An Iranian study,18 published in 2015, found association between higher risk of developing breast cancer and MMP-9 polymorphism, as the presence of mutant allele increased the susceptibility to the disease by 1.87 times (OR = 1.87, IC95: 1.05–3.33, p = 0.035). Similarly, a large meta-analysis,7 also from 2015, showed an association between TT genotype of MMP-9–1562 C/T polymorphism and a higher risk for breast cancer. This result was in contrast to our study, which was supported by a South Brazilian research (p = 0.23)21 and a meta-analysis conducted by Zhou et al,22 which involved more than 5,000 patients. Both studies found no evidence that the 1562 C/T polymorphism (rs3918242) is correlated with a higher risk for breast cancer. Several studies have described the role of MMPs in breast cancer progression and metastasis development, as MMPs are involved in the degradation of basement membranes.23 In a meta-analysis24 including more than 10,000 cancer cases, MMP-9 (1562 C/T) was shown to increase the risk of cancer metastasis, correlating the polymorphism with a more aggressive disease (OR = 1.25, IC95: 1.03 - 1.51, p = 0.07). Our results were inconsistent with this finding, as the adjustment for disease stage did not involve a higher frequency of polymorphism in more advanced tumors (p = 0.4075). A factor with strong involvement that has not yet been established as a risk factor is the use of oral contraceptive, which, in our study, was related to higher occurrence of the disease (p < 0.0001).25 A meta-analysis26 correlating Iranian studies demonstrated that the use of oral contraceptives may stimulate the occurrence of breast cancer because it directly increases estrogen levels and indirectly influences weight gain. Our finding is consistent with the results reported in an analysis27 published in 2016, which showed an OR of breast cancer development that was 54.6% lower in patients who did not use oral contraceptives compared with those who used it. Approximately 5 to 10% of breast cancer cases are familial and occur earlier than those in the general population. The BRCA1 and BRCA2 mutations are primarily responsible for hereditary breast cancer.28 Despite years of research, it has been shown that a minority of patients with a personal or family history of breast cancer have a genetic mutation as an identifiable cause.17 Our study is consistent with the global literature, as we found a positive association of family history with development of the disease (p = 0.004). Stratified analysis according to HER2 or estrogen receptor expression in neoplastic cells showed no relationship with the occurrence of the polymorphism studied, and similarly, Ki67—a tumor cell proliferation index—was not a factor associated with the greater presence of the polymorphic alleles. We believe, however, that more studies are needed to confirm any of the proposed hypotheses due to the lack of evidence in the literature on the subject. Conclusion The main results of this study suggest that the T allele and the TT genotype of 1562 C/T (rs 3918242) of the MMP-9 do not play a key role in breast cancer development. Although research has been performed to explore the role of SNPs of this gene in breast cancer, the results are inconclusive. We note that the controversy remains over the influence of 1562 C/T (rs 3918242) of the MMP-9 on the genesis of breast cancer. More studies and a larger case sample are necessary to confirm the effects on the risk of breast cancer to assist in the screening and follow-up of patients at increased risk of the disease. Acknowledgments The authors would like to thank the patients for their contribution to the research, the anesthesiologist team of the services where the project was developed for the aid in collecting the material, and the interns of the Department of Biochemistry of FMABC for their dedication to the analysis of the material obtained. Contributors Conflicts of Interest This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Felizi R. T., Veiga M. G., Carelli Filho I., Souto R. P., Fernandes C. E. and Oliveira E. contributed with the project and the interpretation of data, writing of the article, critical review of the intellectual content and final approval of the version to be published. ==== Refs References 1 Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva Estimativa 2018: Incidência de Câncer no Brasil. Rio de Janeiro, RJ: INCA; 2017. http://www.inca.gov.br/estimativa/2018/estimativa-2018.pdf. Accessed December 17, 2017 2 Zhou L P Yao F Luan H CYP3A4*1B polymorphism and cancer risk: a HuGE review and meta-analysis Tumour Biol 2013 34 02 649 660. Doi: 10.1007/s13277-012-0592-z23179402 3 Newman B Austin M A Lee M King M C Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families Proc Natl Acad Sci U S A 1988 85 09 3044 3048. Doi: 10.1073/pnas.85.9.30443362861 4 Dunning A M Healey C S Pharoah P DP Teare M D Ponder B AJ Easton D F A systematic review of genetic polymorphisms and breast cancer risk Cancer Epidemiol Biomarkers Prev 1999 8 10 843 854 10548311 5 Belkin A M Akimov S S Zaritskaya L S Ratnikov B I Deryugina E I Strongin A Y Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion J Biol Chem 2001 276 21 18415 18422. Doi: 10.1074/jbc.M01013520011278623 6 Przybylowska K Kluczna A Zadrozny M Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer Breast Cancer Res Treat 2006 95 01 65 72. Doi: 10.1007/s10549-005-9042-616267613 7 Savinov A Y Remacle A G Golubkov V S Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients Cancer Res 2006 66 05 2716 2724 16510592 8 Egeblad M Werb Z New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2002 2 03 161 174. Doi: 10.1038/nrc74511990853 9 Folgueras A R Pendás A M Sánchez L M López-Otín C Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies Int J Dev Biol 2004 48 (5-6):411 424. Doi: 10.1387/ijdb.041811af15349816 10 Lemaître V D'Armiento J Matrix metalloproteinases in development and disease Birth Defects Res C Embryo Today 2006 78 01 1 10. Doi: 10.1002/bdrc.2006516622845 11 Liotta L A Tryggvason K Garbisa S Hart I Foltz C M Shafie S Metastatic potential correlates with enzymatic degradation of basement membrane collagen Nature 1980 284 (5751):67 68 6243750 12 Duffy M J Maguire T M Hill A McDermott E O'Higgins N Metalloproteinases: role in breast carcinogenesis, invasion and metastasis Breast Cancer Res 2000 2 04 252 257 11250717 13 St Jean P L Zhang X C Hart B K Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease Ann Hum Genet 1995 59 (Pt 1):17 24. Doi: 10.1111/j.1469-1809.1995.tb01602.x7762981 14 Zhang X Jin G Li J Zhang L Association between four MMP-9 polymorphisms and breast cancer risk: a meta-analysis Med Sci Monit 2015 21 1115 1123. Doi: 10.12659/MSM.89389025890491 15 Yousef E M Tahir M R St-Pierre Y Gaboury L A MMP-9 expression varies according to molecular subtypes of breast cancer BMC Cancer 2014 14 609. Doi: 10.1186/1471-2407-14-60925151367 16 Zhang B Ye S Herrmann S M Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis Circulation 1999 99 14 1788 1794. Doi: 10.1161/01.CIR.99.14.178810199873 17 Shiovitz S Korde L A Genetics of breast cancer: a topic in evolution Ann Oncol 2015 26 07 1291 1299. Doi: 10.1093/annonc/mdv02225605744 18 Rahimi Z Yari K Rahimi Z Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer Asian Pac J Cancer Prev 2015 16 03 1175 1179 25735351 19 Padala C Tupurani M A Puranam K Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer PLoS One 2017 12 09 e0184448. Doi: 10.1371/journal.pone.018444828961241 20 Merdad A Karim S Schulten H J Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis Anticancer Res 2014 34 03 1355 1366 24596383 21 Roehe A V Frazzon A P Agnes G Damin A P Hartman A A Graudenz M S Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results Breast Cancer Res Treat 2007 102 01 123 124. Doi: 10.1007/s10549-006-9273-117260100 22 Zhou P Du L F Lv G Q Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis Breast Cancer Res Treat 2011 127 03 813 818. Doi: 10.1007/s10549-010-1294-021161369 23 Jones J L Walker R A Control of matrix metalloproteinase activity in cancer J Pathol 1997 183 04 377 379. Doi: 10.1002/(SICI)1096-9896(199712)183:4<377:AID-PATH951>3.0.CO;2-R9496252 24 Liu D Guo H Li Y Xu X Yang K Bai Y Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis PLoS One 2012 7 02 e31251. Doi: 10.1371/journal.pone.003125122348060 25 Key T J Verkasalo P K Banks E Epidemiology of breast cancer Lancet Oncol 2001 2 03 133 140. Doi: 10.1016/S1470-2045(00)00254-011902563 26 Soroush A Farshchian N Komasi S Izadi N Amirifard N Shahmohammadi A The role of oral contraceptive pills on increased risk of breast cancer in Iranian populations: a meta-analysis J Cancer Prev 2016 21 04 294 301. Doi: 10.15430/JCP.2016.21.4.29428053965 27 Cauchi J P Camilleri L Scerri C Environmental and lifestyle risk factors of breast cancer in Malta-a retrospective case-control study EPMA J 2016 7 20. Doi: 10.1186/s13167-016-0069-z27679672 28 Appel S J Cleiment R J Identifying women at risk for hereditary breast and ovarian cancer syndrome utilizing breast care nurse navigation at mammography and imaging centers J Natl Black Nurses Assoc 2015 26 02 17 26 27045154